These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19845040)

  • 1. Candida albicans: fundamental research on an opportunistic human pathogen.
    Calderone R; Odds FC; Boekhout T
    FEMS Yeast Res; 2009 Oct; 9(7):971-2. PubMed ID: 19845040
    [No Abstract]   [Full Text] [Related]  

  • 2. Human fungal pathogen Candida albicans in the postgenomic era: an overview.
    Kabir MA; Hussain MA
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):121-34. PubMed ID: 19622061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida albicans morphology: still in focus.
    Jacobsen ID; Hube B
    Expert Rev Anti Infect Ther; 2017 Apr; 15(4):327-330. PubMed ID: 28152317
    [No Abstract]   [Full Text] [Related]  

  • 4. Betamethasone augments the antifungal effect of menadione--towards a novel anti-Candida albicans combination therapy.
    Jakab Á; Emri T; Sipos L; Kiss Á; Kovács R; Dombrádi V; Kemény-Beke Á; Balla J; Majoros L; Pócsi I
    J Basic Microbiol; 2015 Aug; 55(8):973-81. PubMed ID: 25707543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candida albicans Infection Model in Zebrafish (Danio rerio) for Screening Anticandidal Drugs.
    Kulatunga DCM; Dananjaya SHS; Nikapitiya C; Kim CH; Lee J; De Zoysa M
    Mycopathologia; 2019 Oct; 184(5):559-572. PubMed ID: 31473909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking into Candida albicans infection, host response, and antifungal strategies.
    Wang Y
    Virulence; 2015; 6(4):307-8. PubMed ID: 25590793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Aspartic Proteases in Candida Virulence. Protease Inhibitors against Candida Infections.
    Monika S; Małgorzata B; Zbigniew O
    Curr Protein Pept Sci; 2017; 18(10):1050-1062. PubMed ID: 27514853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida albicans, plasticity and pathogenesis.
    Poulain D
    Crit Rev Microbiol; 2015 Jun; 41(2):208-17. PubMed ID: 23962107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update.
    Dadar M; Tiwari R; Karthik K; Chakraborty S; Shahali Y; Dhama K
    Microb Pathog; 2018 Apr; 117():128-138. PubMed ID: 29454824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis and susceptibility profiling of Candida albicans isolates from immunocompromised patients in South India.
    Girish Kumar CP; Hanafy AM; Katsu M; Mikami Y; Menon T
    Mycopathologia; 2006 Mar; 161(3):153-9. PubMed ID: 16482387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Candida albicans filamentation for antifungal drug development.
    Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
    Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics to study Candida albicans biology and pathogenicity.
    Thomas DP; Pitarch A; Monteoliva L; Gil C; Lopez-Ribot JL
    Infect Disord Drug Targets; 2006 Dec; 6(4):335-41. PubMed ID: 17168799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse intravenous challenge models and applications.
    MacCallum DM
    Methods Mol Biol; 2012; 845():499-509. PubMed ID: 22328398
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Sampaio ADG; Gontijo AVL; Araujo HM; Koga-Ito CY
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candida albicans isolates from a single hospital show low phenotypical specialization.
    Boros E; Pfliegler WP; Kovács R; Jakab Á; Majoros L; Barta Z; Pócsi I
    J Basic Microbiol; 2017 Nov; 57(11):910-921. PubMed ID: 28891112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candida albicans, the opportunist. A cellular and molecular perspective.
    Dupont PF
    J Am Podiatr Med Assoc; 1995 Feb; 85(2):104-15. PubMed ID: 7877106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.
    Li X; Hou Y; Yue L; Liu S; Du J; Sun S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5885-91. PubMed ID: 26195510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida albicans molecular biology reaches its maturity.
    Larriba G; Rubio Coque JJ; Ciudad A; Andaluz E
    Int Microbiol; 2000 Dec; 3(4):247-52. PubMed ID: 11334309
    [No Abstract]   [Full Text] [Related]  

  • 19. Antifungal susceptibility of Candida albicans in biofilms.
    Tobudic S; Kratzer C; Lassnigg A; Presterl E
    Mycoses; 2012 May; 55(3):199-204. PubMed ID: 21793943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced susceptibility of Candida albicans clinical isolates to azoles and detection of mutations in the ERG11 gene.
    Zhang L; Yang HF; Liu YY; Xu XH; Ye Y; Li JB
    Diagn Microbiol Infect Dis; 2013 Dec; 77(4):327-9. PubMed ID: 24070847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.